Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers
Latin american journal of clinical sciences and medical technology · 2020
DOI: 10.34141/ljcs1055083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Latin american journal of clinical sciences and medical technology, 2020. Verfasst von Suset J. Tolentino-Hernández und 3 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Oral ciprofloxacin extended-release formulation decreases the risk of treatment failure and prevents the development of antimicrobial resistance. However, non-equivalent formulations lead to subtherapeutic plasma drug concentrations, increasing the risk of such problems.
Objective
To determine the bioequivalence of two oral ciprofloxacin extended-release tablet formulations (1,000 mg) in healthy Mexican volunteers. Material and Methods. In this open-label 2 × 2 crossover design study, 26 healthy volunteers were randomly allocated to receive a single dose of the reference drug Cipro XR® (Bayer, Mexico) and the test formulation Ciproflox DM® (Senosiain Laboratories, Mexico). Blood samples were obtained for 24 hours. Ciprofloxacin plasma levels were quantified using a validated liquid chromatography method. Pharmacokinetic parameters were obtained by standard non-compartmental analysis. In order to determine bioequivalence, log-transformed test/reference ratios of Cmax, AUC0-t, and AUC0-inf were compared by an analysis of variance, followed by the 90 % confidence intervals and the Schuirmann bilateral test.
Results
The 90 % confidence intervals ranged from 85.69 to 114.31 % for Cmax, 85.16-115.84 % in AUC0-t, and 85.39-114.61 % for AUC0-inf, all cases were within bioequivalence acceptance criteria (80-125 %). Schuirmann test verified the probability that the values were within these criteria (p < 0.05). No side-effects were observed with any treatment.
Conclusions
The results obtained demonstrate bioequivalence between the analyzed formulations.
Zitieren
APA
Tolentino-Hernández, S. J., Cruz-Antonio, L., Torres-Roque, I., & Pérez-Urizar, J. T. (2020). Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers. Latin american journal of clinical sciences and medical technology. https://doi.org/10.34141/ljcs1055083
Vancouver
Tolentino-Hernández SJ, Cruz-Antonio L, Torres-Roque I, Pérez-Urizar JT. Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers. Latin american journal of clinical sciences and medical technology. 2020. doi:10.34141/ljcs1055083
BibTeX
@article{TolentinoHernndez2020,
author = {Tolentino-Hernández, Suset J. and Cruz-Antonio, Leticia and Torres-Roque, Irma and Pérez-Urizar, José T.},
title = {Bioequivalence of Two Oral Ciprofloxacin Extended-Release Formulations in Healthy Mexican Volunteers},
journal = {Latin american journal of clinical sciences and medical technology},
year = {2020},
doi = {10.34141/ljcs1055083}
}
EUVIMED